Business Context and Reporting Period
This Form 8-K was filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on September 5, 2012. The report discloses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on director compensation and appointment details.
Material Changes
- Board Expansion: The Board of Directors increased its size from four to five authorized directors.
- New Appointment: Ted W. Love, M.D., was appointed as an independent director, effective immediately.
- Compensation Structure: Dr. Love will receive an annual cash retainer of $20,000 (pro-rated for Q3 2012) and $1,000 per Board meeting attended.
- Stock Options:
- Inducement Option: 18,895 shares vesting over 36 months.
- Pro-rated Annual Option: 14,171 shares vesting over 9 months.
- Exercise Price: $0.69 per share (closing price on September 5, 2012).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The only contingency noted is that the stock options will vest immediately prior to a change of control if Dr. Love is providing services at that time.
Investor Verification Checklist
- Verify the correct registrant name is ADVENTRX Pharmaceuticals, Inc., not Savara Inc.
- Confirm the total number of shares authorized for issuance under the 2008 Omnibus Incentive Plan to assess dilution impact.
- Review the company's cash position to ensure it can support the new director cash retainers.
- Check subsequent filings for any changes to Dr. Love's committee assignments or service status.